New weight-loss pill shows promising results

Oxford Medical Products targets overweight individuals

Oxford Medical Products has announced positive three-month clinical trial results for Sirona, a weight-loss treatment aimed at overweight individuals and those transitioning off GLP-1 medications.

The trial, conducted across three NHS hospitals, showed participants experienced sustained weight loss. People with class 1 obesity lost on average 6.3% of their total body weight.

Sirona is a dual-polymer hydrogel pill that expands in the stomach, reducing appetite. Participants consumed 400 fewer calories per day compared to those on a placebo. Early data suggests a potential 10-12% total body weight loss at 52 weeks. The trial reported no serious adverse events, with 96% of patients adhering to the dosing regimen.

Dr Camilla Easter, CEO of Oxford Medical Products said: “OMP is at a pivotal moment, with our promising early clinical data showcasing Sirona’s potential as a safe and effective weight loss treatment.” Sirona targets the majority of adults with a BMI of 25-35, a group often overlooked by GLP-1 medications. 43% of global adults fall into this overweight category.

Dr Asif Humayun, an NHS endocrinologist, said: “Sirona represents a new generation in weight-loss therapeutics, specifically for obese patients and their resulting comorbidities.”

He added that the early trial results were promising. Sirona is positioned as a solution for individuals transitioning off GLP-1s, preventing weight regain. 65% of weight lost on GLP-1s is typically regained within 12 months.

Ruth, a trial participant, said: “During the trial, my BMI went from 37.7 to 31.2.” Oxford Medical Products plans to advance Sirona into a larger pivotal trial in the US and UK later this year. The company aims to provide a safe and effective weight-loss solution for millions.